Abstract:Upregulated expression of immune checkpoint molecules correlates with exhausted phenotype and impaired function of cytotoxic T cells to evade host immunity. By disrupting the interaction of PD-L1 and PD1, immune checkpoint inhibitors can restore immune system function against cancer cells. Growing evidence have demonstrated apigenin and luteolin, which are flavonoids abundant in common fruits and vegetables, can suppress growth and induce apoptosis of multiple types of cancer cells with their potent anti-inflammatory, antioxidant and anticancer properties. In this study, the effects and underlying mechanisms of luteolin, apigenin, and anti-PD-1 antibody combined with luteolin or apigenin on the PD-L1 expression and anti-tumorigenesis in KRAS-mutant lung cancer were investigated. Luteolin and apigenin significantly inhibited lung cancer cell growth, induced cell apoptosis, and down-regulated the IFN-γ-induced PD-L1 expression by suppressing the phosphorylation of STAT3. Both luteolin and apigenin showed potent anti-cancer activities in the H358 xenograft and Lewis lung carcinoma model in vivo, and the treatment with monoclonal PD1 antibody enhanced the infiltration of T cells into tumor tissues. Apigenin exhibited anti-tumor activity in Genetically engineered KRASLA2 mice. In conclusion, both apigenin and luteolin significantly suppressed lung cancer with KRAS mutant proliferation, and down-regulated the IFN-γ induced PD-L1 expression. Treatment with the combination of PD-1 blockade and apigenin/luteolin has a synergistic effect and might be a prospective therapeutic strategy for NSCLC with KRAS-mutant.

What problem does this paper attempt to address?

The main problems that this paper attempts to solve are to explore the inhibitory effects of flavonoids apigenin and luteolin on PD - L1 expression in KRAS - mutant non - small - cell lung cancer (NSCLC) and their underlying mechanisms, as well as the inhibitory effects on tumor growth when these compounds are used in combination with anti - PD - 1 antibodies. Specifically, the research focuses on the following aspects: 1. **Effects of apigenin and luteolin on the proliferation and apoptosis of KRAS - mutant NSCLC cells**: Through MTT assay and colony - formation assay, the proliferation - inhibitory effects of apigenin and luteolin at different concentrations on KRAS - mutant NSCLC cell lines (such as H358, H460, A549) were studied, and cell apoptosis was detected by flow cytometry. 2. **Inhibitory effects of apigenin and luteolin on the MUC1 - C/STAT3 signaling pathway**: Through Western Blot experiment, the inhibitory effects of apigenin and luteolin on the protein expressions of MUC1 - C and PD - L1 were studied, and their inhibitory effects on STAT3 phosphorylation were further explored. 3. **Inhibitory effects of apigenin and luteolin on IFN - γ - induced PD - L1 expression**: Through qPCR and flow cytometry, the inhibitory effects of apigenin and luteolin on IFN - γ - induced PD - L1 mRNA and protein expressions were studied, and the binding abilities of apigenin and luteolin to STAT3 were predicted by molecular docking. 4. **Inhibitory effects of apigenin and luteolin on tumor growth in vivo**: Through H358 xenograft tumor model and Lewis lung cancer model, the anti - tumor effects of apigenin and luteolin in vivo were studied, including the effects on tumor volume, weight and mouse survival rate. 5. **Synergistic effects of apigenin and luteolin in combination with anti - PD - 1 antibodies**: Through combination treatment experiments, the inhibitory effects on tumor growth when apigenin or luteolin was used in combination with anti - PD - 1 antibody, as well as the effects on CD8+T cell infiltration and activation were studied. 6. **Anti - tumor activities of apigenin and luteolin in KRASLA2 mouse model**: Through KRASLA2 mouse model, the anti - tumor effects of apigenin and luteolin in genetically engineered mice were studied, including the inhibitory effects on tumor growth and the effects on CD8+T cell activation. In summary, this paper aims to explore the multi - faceted effects of apigenin and luteolin on KRAS - mutant NSCLC, especially their inhibitory effects on PD - L1 expression and their potential for use in combination with immune checkpoint inhibitors.

Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer

Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.

KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer

Luteolin is Effective in the Non‐small Cell Lung Cancer Model with L858R/T790M EGF Receptor Mutation and Erlotinib Resistance

Anlotinib enhanced CD8 + T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity Via Immunogenic Cell Death and Macrophage Reprogramming

KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer

KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC

Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway

KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8 + T-cell-dependent antitumor immunity

Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer

PARP inhibition induces synthetic lethality and adaptive immunity in LKB1-mutant lung cancer

Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling

Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non–Small Cell Lung Cancer

Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro

Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer

CRISPR/Cas-Mediated Knockdown of PD-L1 and KRAS in Lung Cancer Cells

The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‐1 antibody suppresses the progression of non‐small cell lung cancer tumors by enhancing immunocompetence

Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy

PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway

Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer